Gene Therapy for Malignant Tumors: Focused on Immunostimulatory Oncolytic Coxsackievirus A11 (CVA11)

Gene Therapy Platforms in Oncology

Gene therapy for cancer can be categorized into several major therapeutic methods.

Gene addition and gene replacement. This approach involves the delivery of functional tumor suppressor genes – such as TP53 or PTEN – to restore regulatory pathways lost during tumorigenesis. Viral vectors such as adenoviruses have been used to deliver p53 into tumors, leading to cell-cycle arrest and apoptosis (6).

Gene silencing and gene editing. RNA interference (RNAi) and CRISPR/Cas systems enable suppression of oncogenes or correction of pathogenic mutations. These methods can disrupt oncogenic drivers such as KRAS, MYC, or BCL2, thereby inhibiting malignant growth (7, 8).

Suicide gene therapy. This approach involves engineering tumor cells to express suicide genes, such as herpes simplex virus thymidine kinase, which convert nontoxic prodrugs into cytotoxic metabolites, thereby selectively inducing apoptosis in transduced tumor cells (9).

Immune gene therapy. Gene-based immunotherapy delivers cytokines (e.g., IL-2, IL-12), costimulatory molecules, or tumor antigens to enhance antitumor immunity (9). This approach overlaps significantly with cancer vaccination strategies.

Oncolytic virotherapy. OVs exploit defects in tumor antiviral defenses while sparing normal tissues. They lyse cancer cells, release tumor antigens, promote immune infiltration, and create a pro-inflammatory microenvironment (10, 11).

Among all gene therapy approaches, OVs uniquely combine direct cytolysis and immune activation, offering distinct biological advantages. This dual mechanism makes OVs particularly attractive as combination partners with chemotherapy, radiotherapy, immune checkpoint inhibitors, and cancer vaccines.

Coxsackievirus A11 as a Potent Immunostimulatory Oncolytic Virus

A 2023 Scientific Reports article identified CVA11 as a highly potent OV with both cytolytic and immunostimulatory functions (5). Several biological properties distinguish CVA11 from other OVs as follows.

Tumor-selective tropism. CVA11 infects NSCLC cells efficiently due to the expression of specific viral receptors. Although the exact receptor profile for CVA11 requires further elucidation, studies suggest similarities to other Coxsackie A viruses, which bind ICAM-1–like molecules on tumor cells (12).

Intratumoral replication. CVA11 replicated vigorously within tumor tissues, reaching high titers that allowed consistent and rapid oncolysis. This characteristic is critical because effective OVs must amplify within tumors to achieve therapeutic levels (5).

Induction of pro-inflammatory cytokines. CVA11 stimulates a strong innate immune response, including type I interferons, TNF-α, and other inflammatory cytokines that enhance antigen presentation and immune activation (5).

Recruitment of immune effector cells. OV infection triggers infiltration of CD8+ T cells, NK cells, and macrophages into the tumor microenvironment. These immune populations synergize with viral oncolysis to eliminate residual malignant cells (13). CVA11 is likely to have the same responses.

Complete tumor regression and overcoming chemoresistance in colorectal cancer. Achieving complete tumor regression in xenograft models is rare for OVs and highlights CVA11’s aggressive antitumor potential (5). This finding is noteworthy because NSCLC is typically considered poorly immunogenic. Collectively, these features position CVA11 as one of the most promising natural OVs identified to date.

Chemoresistance represents a major barrier in colorectal cancer treatment. Wang and Ogata et al. showed that CVA11 enhances the cytotoxic effects of oxaliplatin in oxaliplatin-resistant human colorectal cancer (14). Possible mechanisms include the enhanced apoptosis through combined viral and chemotherapeutic insult. This supports the concept that OVs can sensitize resistant tumors to existing therapies.

Other Coxsackieviruses in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is notorious for its dense stroma, which is composed largely of cancer-associated fibroblasts (CAFs). CAFs contribute to drug resistance and immune exclusion. Ogata et al. demonstrated that Coxsackievirus B3 (CVB3) effectively lysed both pancreatic cancer cells and CAFs (15). This dual targeting is significant because most therapeutic agents fail to penetrate PDAC stroma, and few OVs show activity against CAFs. Although CVA11 has not been tested extensively in the stromal-rich tumors such as pancreatic cancer, its biological similarity to CVB3 suggests potential applicability. It may be engineered or selected for activity in tumors characterized by dense stroma or chemoresistance.

Gene-based Cancer Vaccines and Integration With Oncolytic Viruses

Cancer vaccines have basically been explored as a method for generating specific and durable antitumor immunity. Gene-encoded vaccines – delivering DNA, RNA, or viral vectors expressing tumor antigens – are especially promising. Murahashi et al. conducted a clinical trial evaluating a vaccine targeting VEGF and KIF20A in advanced biliary tract cancer (16). Although clinical responses were mild, the trial demonstrated: the induction of antigen-specific T-cell responses, feasibility of multi-antigen vaccination, and potential for combination with other immunotherapies.

OVs act as natural adjuvants for cancer vaccines because they release tumor antigens during oncolysis (17), and promote antigen-presenting cell activation by driving T-cell infiltration (2, 10). Also, they increase MHC expression on tumors (18). CVA11’s potent immunostimulatory profile suggests it could serve as an excellent platform for cancer vaccine augmentation.